New Test to Predict Primary Melanoma Progression
21 January 2020
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
A joint study led by researchers from Melanoma Institute Australia, The University of Sydney, Harvard Medical School, Sydney Local Health District and Adaptive Biotechnology analysed immune cells (known as T-cells) in primary melanoma samples taken from 209 patients, 164 of whom came from MIA.
The study, published today in Nature Cancer, found that patients with a T-cell fraction (TCFr) of less than 20% in their primary melanoma were two-and-a-half times more likely to have disease progression than those with more than 20% TCFr.
The study was jointly led by Dr James Wilmott and Co-Medical Director Professor Richard Scolyer from Melanoma Institute Australia and researchers from Harvard Medical School.
‘These findings suggest analysing TCFr in primary melanomas is a valuable tool for predicting which patients are at risk of developing metastatic melanoma, ’ Dr Wilmott said.
‘This could enable us to personalise treatment for each patient based on their individual risk of recurrence and progression, and potentially target them earlier with immunotherapy,’ Professor Scolyer added.
Australia has one of the highest melanoma rates in the world, with one person diagnosed every 30 minutes and one person dying every five hours from disease.
While 90% of early stage melanomas are cured with surgery alone, a subset of patients will recur metastatically within five years.
Recent advances in targeted and immunotherapies have significantly improved outcomes for Stage IV melanoma patients. However, the management of primary melanoma has remained relatively unchanged, with prognosis based principally on histopathological factors such as tumour thickness and ulceration.
‘This test offers the ability to identify primary melanoma patients at high risk of developing metastatic disease at their initial diagnosis,’ Dr Wilmott said. ‘These patients may benefit from close monitoring or the addition of adjuvant treatments to prevent their disease progressing.’
It's time to march for a cure!
Join us for our fourth annual Melanoma March and help us raise over $1 million for melanoma research as we march for a cure!
Making a difference
When Melanoma Institute Australia (MIA) patients at the Poche Centre are first diagnosed with advanced melanoma Anna Hoadley is there.
New trial offers hope to Stage IV patients
Shining new hope for patients with advanced stage melanoma.
Combination drug therapy halts disease in advanced melanoma
A world-first study in the New England Journal of Medicine heralds the effectiveness of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.
Georgina Long wins award for Outstanding Cancer Research
Associate Professor Georgina Long wins award for Cancer Institute NSW
Melanoma survivors walk from Sydney to Melbourne to raise money
Melanoma survivors and long-time friends Jay Allen and Andrew Rust concluded their 900km walk from Sydney to Melbourne completing their walk at the Melbourne Cricket Ground on Saturday 26 July.
The Federal Government's 2015-16 Budget announcements benefit research
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
Melanoma Essentials eBook offered for Free during EADO and GAC (PDF)
Melanoma Essentials eBook offered for Free during EADO and GAC
Sunrise features inspiring story of MIA patient
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Dr James Wilmott wins award for Outstanding Cancer Research
Dr James Wilmott was awarded the Wildfire Award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
Tune into Jay's Longest Melanoma March Channel 10 documentary - Copy
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
All Aussies should have access to this lifesaver
Carrie Palmer writes for The Daily Telegraph about her experience with melanoma.
15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma
Julie-Ann Sams knows all too well that melanoma doesn’t discriminate. Life changed for her
youngest son, Toby Rayner, when he was diagnosed with a rare from of iris melanoma that sadly required his left eye to be surgically removed.
15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma
Julie-Ann Sams knows all too well that melanoma doesn’t discriminate. Life changed for her
youngest son, Toby Rayner, when he was diagnosed with a rare from of iris melanoma that sadly required his left eye to be surgically removed.
Congratulations to our Conjoint Medical Directors
Our Conjoint Medical Directors have been announced as Fellows of the Australian Academy of Health and Medical Sciences.
Melanoma diagnosis for Australian Survivor Contestant stark warning about the risks of sun exposure
News reports today of a recently evicted Australian Survivor star being diagnosed with melanoma should serve as a stark warning to all Australians of the serious health risks posed by sun exposure.
60 Minutes' MIA Patient Feature Program
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
The latest research from Dr James Wilmott
Dr James Wilmott is researching how melanoma forms in young people.